News | May 14, 2025
Bayer confirms 2025 targets after solid start to the year
EBITDA before special items decreases to €4.08 billion (7.4%)
EBITDA before special items decreases to €4.08 billion (7.4%)
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Yesafili, received marketing authorization approval from the European Commission for the European Union
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Subscribe To Our Newsletter & Stay Updated
